BPA Call HT941024A0007-HT941026FE015

The Defense Health Agency awarded a $13,812.68 firm fixed-price blanket purchase agreement call to Ortho Clinical Diagnostics K.K. on January 6, 2026, for chemistry and immunoassay testing system reagents and supplies. The contract, with a completion date of January 16, 2026, supports laboratory diagnostic operations at U.S. military medical facilities throughout Japan. This award is issued under Ortho Clinical Diagnostics K.K.'s existing $2.875 million single-award BPA with the Defense Health Agency, effective July 1, 2024, through June 30, 2029, which was established to provide VITROS testing system reagents and consumable supplies for locations including Yokota Air Base and other military medical installations across Japan. No socioeconomic set-aside designation applies to this award.

Ortho Clinical Diagnostics K.K., a Japanese subsidiary of the global in vitro diagnostics provider Ortho Clinical Diagnostics, serves as the primary supplier of laboratory diagnostic materials to the Defense Health Agency and related defense medical commands throughout the Indo-Pacific region. The company maintains an established track record spanning 2021 through 2025, supplying critical VITROS chemistry and immunoassay testing reagents to naval hospitals, air force bases, and military medical research centers in Japan. Performance occurs at facilities in Japan, with the company holding multiple active indefinite-delivery vehicles totaling approximately $7.2 million in potential value across the Defense Health Agency, Department of Navy Bureau of Medicine and Surgery, and Pacific Air Forces, all awarded on a firm fixed-price basis without set-aside designations.